Ferumoxytol for Treating Iron Deficiency Anemia in CKD

Spinowitz, Bruce; Kausz, Annamaria T.; Baptista, Jovanna; Noble, Sylvia; Sothinathan, Renuka; Bernardo, Marializa; Brenner, Louis; Pereira, Brian J.G.

doi:10.1681/asn.2007101156

Cited by 235 publications

(185 citation statements)

References 39 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…iron is limited by the complexity of the procedure (need for multiple doses or long infusion times) and therefore avoided by many medical practitioners. To solve this issue, a new iron formulation that can be given in amounts of 510 mg over Ͻ1 minute has been developed [33]. Efficacy was measured early, at day 35, because Ͼ1 g of iron could be administered i.v.…”

Section: Efficacy and Safety Of IV And Oral Iron In Ckd Patients Nomentioning

confidence: 99%

Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome

2009

View full text Add to dashboard Cite

In treating moderate to severe anemia of chronic kidney disease (CKD), oral iron is effective only in a minority of nondialysis patients. Intravenous iron is more effective and can raise levels of hemoglobin even without the use of erythropoiesis-stimulating agents (ESAs). Unfortunately, the current assays of iron status that are presently widely available are not especially helpful in predicting response. In patients on dialysis, i.v. iron is effective over a wide range of serum ferritin from <100 ng/ml to 800 ng/ml. None of the three available randomized controlled trials comparing oral with i.v. iron showed evidence of nephrotoxicity caused by i.v. iron.Iron deficiency is a risk factor for thrombocytosis and should, wherever possible, be avoided. Optimal coadministration of iron may reduce the risk for ESA-driven cardiovascular events. Increased total body iron stores (imperfectly reflected by serum ferritin levels in CKD) do not appear to be related to such events or hospitalization in CKD; it is unclear what other risk factors and mechanisms need to be considered.In the appreciable proportion of patients with both renal and cardiac dysfunction, management is further complicated by a vicious circle (which can be characterized as cardiorenal anemia syndrome) in which CKD, heart failure, and anemia exacerbate each other. In such patients, correction of anemia appears to improve cardiac function and quality of life without a greater risk for adverse events. The Oncologist 2009;14(suppl 1):22-33

show abstract

Section: Efficacy and Safety Of IV And Oral Iron In Ckd Patients Nomentioning

confidence: 99%

Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome

2009

View full text Add to dashboard Cite

show abstract

“…The increase in Hb at day 35, the primary efficacy end point, was 0.82+/-1.24 g/dL with ferumoxytol and 0.16+/-1.02 g/dL with oral iron (P<0.0001). 17 The authors concluded that a regimen of two doses of 510 mg of intravenous ferumoxytol administered rapidly within 5±3 days was well tolerated and had the intended therapeutic effect. The side effects associated with IV iron in the abovementioned studies were headache, myalgia, and hypotension (particularly in thin, older women<65 kg).…”

Section: Anemia In Chronic Kidney Diseasementioning

confidence: 99%

“…Oral iron has more GI associated side effects including constipation, diarrhea, nausea and vomiting. [13][14][15][16][17] As a result of these studies the K/DOQI guidelines have recommended that either oral iron therapy or intravenous iron therapy can be given in CKD patients.…”

Section: Anemia In Chronic Kidney Diseasementioning

confidence: 99%

See 1 more Smart Citation

Pharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease

Siddiqui¹,

Siddiqui²,

Benz³

2012

Chronic Kidney Disease

View full text Add to dashboard Cite

“…It was approved by the U.S. Food and Drug Administration as an IV treatment of iron-deficiency anemia in patients with chronic kidney disease [2,3]. Ferumoxytol is an attractive alternative to standard gadolinium-based MRI contrast agents that carry potential risks if given to patients with renal failure [4][5][6].…”

mentioning

confidence: 99%

Vascular Inflammation in a Growing Iliac Artery Aneurysm

Hope

Gasper²,

Rapp³

et al. 2015

Clinical Nuclear Medicine

View full text Add to dashboard Cite

can be applied to vessel wall imaging [16]. The goal of this article is to summarize more than 3 years of clinical experience with ferumoxytol-enhanced MR angiography (MRA) at our institution for a range of applications including standard clinical indications (i.e., pulmonary embolism, aorta, coronary and peripheral vascular imaging) and advanced research topics (i.e., 4D flow imaging and imaging to detect vascular inflammation). Subjects and Imaging TechniquesThis study was approved by the institutional review board at our facility and is compliant with HIPAA. A total of 102 patients underwent MRA with ferumoxytol (Feraheme, AMAG Pharmaceuticals) between December 2010 and January 2015. Informed consent for the use of ferumoxytol was acquired for all examinations, and medical records were reviewed to rule out iron overload and other potential contraindications for MRI or for USPIO administration.The clinical indications for the examinations were evaluation of abdominal aortic aneurysms (AAAs) (30 patients, 29.4%), thoracoabdominal aortic aneurysms (three patients, 2.9%), pulmonary embolism (eight patients, 7.8%), aortic dissection (two patients, 2.0%), intracranial aneurysms (two patients, 2.0%), arteriovenous fistulas (15 patients, 14.7%), coronary arteries (four patients, 3.9%), carotid arteries (11 patients, 10.8%), and lower extremity vasculature (27 patients, 26.5%). The mean age of the study group was 70.7 ± 10.5 (SD) years (range, 47-95 years); there were

show abstract

Ferumoxytol for Treating Iron Deficiency Anemia in CKD

Cited by 235 publications

References 39 publications

Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome

Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome

Pharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease

Vascular Inflammation in a Growing Iliac Artery Aneurysm

Contact Info

Product

Resources

About